Research Disclosures & Disclaimers

This website contains disclosures and disclaimers related to
published UBS Global Research products, including those related to
regulation, potential conflicts of interest as well as those provided
by third-party data providers describing limitations on use of their
products.

Novo Nordisk (NOVOb.CO)*

UBS Rating and Price Target History Chart

Line chart explaining Price target vs Stock Price is described in below table

EQ Rating & Price Target Table

Date	Stock Price (DKr)	Price Target (DKr)	Rating
2022-02-11	327.50	330.00	Neutral
2022-02-14	321.55	315.00	Neutral
2022-06-28	387.00	350.00	Sell
2023-01-09	478.85	340.00	Sell
2023-05-26	568.80	360.00	Sell
2024-01-15	725.60	795.00	Neutral
2024-06-28	1005.60	1100.00	Neutral
2025-01-08	619.50	750.00	Buy
2025-05-08	428.90	700.00	Buy

Disclosures

Within the past 12 months, UBS has received compensation for products and services other than investment banking services from this company/entity.
UBS Securities LLC makes a market in the securities and/or ADRs of this company.
UBS holds a long or short position of 0.5% or more of the listed shares of this company.

Note : Historical Price Targets have been adjusted to account for any stock splits, rights issues and/or dividends which may have occurred for this security. Not Priced: Stock was not priced on the given date. No Rating: Issuer was not rated by UBS on the given day. No Price Target: For this issuer no Price Target was set by UBS on the given day. Issuers with an EQ Rating & Price Target Table are covered by UBS-IB Equity Research Analysts. Issuers without an EQ Rating & Price Target Table are not single stock covered.

* Issuers marked with an asterisk are covered by UBS-IB Equity Research Analysts. Issuers without an asterisk are not single stock covered.